European Journal of Molecular & Clinical Medicine

The object of the study were 97 patients, children with community-acquired pneumonia associated with mycoplasma and chlamydial infection aged from 1 to 7 years. Dynamic analysis has proven the benefit of differentiated treatment. In group II, during therapy on the 6th day from the start of treatment, a pronounced positive dynamics of physical data was observed. Analysis of the effect of differentiated treatment on the parameters of biochemical data of the examined patients revealed a positive effect on the studied parameters. There was a significant decrease in the content of NO₂(NO₃), HP, ONOO- and a significant increase in eNOS compared with the data of group I. After treatment, the concentration of MDA was 1.8 times higher than in practically healthy children and 1.4 times lower than in children who received basic therapy. A decrease in the level of MDA in the blood in patients with CAP associated with MI and CI during treatment states a decrease in free radicals and an increase in the intensity of AOS.

The aim of the study was to study the effectiveness of the use of protected cephalosporin III generation Extum in the treatment of community-acquired pneumonia in children. The study included 100 children with community-acquired pneumonia at the age from 1 to 15 years, who were observed and treated in the department of pulmonology. In the process of complex clinical and laboratory examination of children, biochemical, microbiological and immunological research methods were used. Microbiological studies have shown that in children with community-acquired pneumonia, S. Pneumonia occupies a significant place in the etiological structure and accounts for 42.0% of cases, a high sensitivity of pneumococcus to injectable cephalosporin of the third generation has been established. When included in complex treatment, protected cephalosporin of the third generation Extum leads to a decrease in the frequency of repeated acute respiratory infections and their complications by 2.2 times, the frequency of recurrent bronchitis and pneumonia by 1.7 times, which indicates a high therapeutic effectiveness of the proposed treatment

Pneumonia is a disease that has an acute course and is characterized by an infectious and inflammatory lesion of the lungs. The high level of one-stage morbidity of community-acquired pneumonia, mainly in the variant of severe and life-threatening course in combination with concomitant pathology (75.4%), causes significant damage to the health of the population and deaths are observed in 6.7%. The problem of manifestations of long-term results of pneumonia is becoming increasingly relevant today in connection with the sharply increased rate and intensity of working activity of people, improving the quality of work, as well as environmental pollution and concomitant pathology also leaves its mark on human health. In case of community-acquired pneumonia, the concomitant pathology will influence the long-term results, further observation of these patients will show for 2, 3 years, depending on the severity of the course.